|1.||Hornemann, Thorsten: 5 articles (05/2013 - 04/2009)|
|2.||Timmerman, Vincent: 5 articles (05/2013 - 10/2002)|
|3.||Nicholson, Garth A: 4 articles (07/2014 - 10/2002)|
|4.||Auer-Grumbach, Michaela: 4 articles (05/2013 - 10/2002)|
|5.||Park, Tae-Sik: 3 articles (07/2015 - 07/2008)|
|6.||Penno, Anke: 3 articles (06/2011 - 04/2009)|
|7.||Rotthier, Annelies: 3 articles (06/2011 - 04/2009)|
|8.||Jiang, Xian-Cheng: 2 articles (09/2015 - 04/2013)|
|9.||Geekiyanage, Hirosha: 2 articles (08/2013 - 10/2011)|
|10.||Chan, Christina: 2 articles (08/2013 - 10/2011)|
01/01/2012 - "Focussing on genes in the latter class, RNAi-mediated knockdown of the small GTPase Rab5, the prenylated SNARE protein YKT6, one sub-unit of serine palmitoyltransferase (spt2/lace), the Rac1-associated protein Sra1 and the actin cytoskeleton regulatory protein, SCAR, all lead to a significant reduction in parasite phagocytosis. "
04/01/2013 - "Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosis."
07/01/1986 - "Thus, the accumulation of sphingomyelin that occurs in aorta during experimental atherogenesis may be related to increased long-chain base synthesis by serine palmitoyltransferase."
07/01/1986 - "Enzymology of long-chain base synthesis by aorta: induction of serine palmitoyltransferase activity in rabbit aorta during atherogenesis."
09/11/2009 - "Conversely, atherosclerosis is reduced in mice by blocking de novo synthesis of sphingolipids catalyzed by serine palmitoyltransferase (SPT). "
12/01/1987 - "These experiments demonstrate that L-cycloserine inhibits serine palmitoyltransferase in aorta, and thus may be used to reduce sphingomyelin concentrations during experimental atherogenesis."
|3.||Melanoma (Melanoma, Malignant)
01/15/2012 - "In a previous study, myriocin, an inhibitor of serine palmitoyltransferase, was found to suppress melanoma cell proliferation by cell cycle arrest at the G 2/M phase through decreased sphingolipid levels and increased p53 and p21 (waf1/cip1) expression. "
08/01/2011 - "Here, we have investigated anti-proliferative activity of myriocin, serine palmitoyltransferase inhibitor, in the de novo sphingolipid pathway, and its mechanism in B16F10 melanoma cells. "
08/01/2011 - "Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2) /M phase arrest."
01/15/2012 - "Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis."
|4.||Wounds and Injuries (Trauma)
01/01/2013 - "The objective of this study was to examine the effects of short (2 h) and prolonged (18 h) inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate (PA) induced insulin resistance in L6 myotubes. "
01/01/2013 - "Effects of inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate induced insulin resistance in L6 myotubes."
|1.||GTP Phosphohydrolases (GTPases)
|3.||Apolipoproteins E (ApoE)
|5.||Cytochrome P-450 CYP1A1 (CYP1A1)
|6.||Proteins (Proteins, Gene)